Related Experiment Video
Updated: Sep 21, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
[Effects of GSK3β/eEF2K signaling pathway on pulmonary fibrosis in mice]
Chao-Qun Qin1, Bin Huang1, Fang Yang1
1Guilin People's Hospital, Guilin 541002, China.
Abstract:
Objective: To investigate the effects of glycogen synthase kinase-3β (GSK3β)/eukaryotic extension factor kinase 2 (eEF2K) signaling pathway on the process of pulmonary fibrosis through in vivo experiments, and find new ideas for clinical treatment of pulmonary fibrosis. Methods: The pulmonary fibrosis model of C57BL/6 male mice was induced by bleomycin with intratracheal injection at the dose of 2 mg/kg. After 14 days of modeling, animals were divided into model group, negative inhibition group and inhibition group (n=5 for each group), and control group was not processed. The inhibition group was treated with TDZD-8 (4 mg/kg) after modeling, the negative inhibition group was given DMSO solution after modeling, and the samples were collected after 28 days. Hematoxylin-eosin staining method was used to detect lung fibrosis in mice and scored according to Ashcroft scale. Expression levels of GSK3β, p-GSK3β, eEF2K, p-eEF2K (Ser70, Ser392, Ser470), precursor protein of matrix metalloproteinase-2 (pro-MMP-2), matrix metalloproteinase-2 (MMP-2), collagen I (Col I), collagen Ⅲ (Col Ⅲ) and α-smooth muscle actin (α-SMA) were detected by Western blot. Results: Compared with control group, the fibrosis score was up-regulated, the expression levels of GSK3β, p-GSK3β, p-eEF2K (Ser70, Ser392, Ser470), pro-MMP-2, MMP-2, Col I, Col Ⅲ and α-SMA were increased, while that of eEF2K was decreased in model group (P<0.05). Compared with model group, the fibrosis score, expression levels of GSK3β, p-GSK3β, p-eEF2K (Ser70, Ser392, Ser470), pro-MMP-2, MMP-2, Col I, Col Ⅲ and α-SMA were decreased, but the expression level of eEF2K was increased in inhibition group (P<0.05). Conclusion: GSK3β can activate eEF2K by phosphorylation at the sites of Ser70, Ser392 and Ser470, increase the contents of fibrosis indicators, promote the formation of pulmonary fibrosis, and aggravate lung tissue lesions.
Insights
This study reveals that glycogen synthase kinase-3β (GSK3β) activates eukaryotic extension factor kinase 2 (eEF2K), promoting pulmonary fibrosis. Inhibiting this pathway reduces fibrosis indicators and lung damage, offering new therapeutic targets for pulmonary fibrosis.
Area of Science:
- Pulmonary Medicine
- Cellular Signaling
- Fibrosis Research
Background:
- Pulmonary fibrosis is a progressive lung disease with limited treatment options.
- The role of the glycogen synthase kinase-3β (GSK3β)/eukaryotic extension factor kinase 2 (eEF2K) signaling pathway in pulmonary fibrosis is not fully understood.
Purpose of the Study:
- To investigate the involvement of the GSK3β/eEF2K signaling pathway in pulmonary fibrosis.
- To explore potential therapeutic strategies targeting this pathway for pulmonary fibrosis treatment.
Main Methods:
- A bleomycin-induced pulmonary fibrosis mouse model was established.
- Mice were treated with TDZD-8, a GSK3β inhibitor.
- Lung fibrosis was assessed using Hematoxylin-eosin staining and Ashcroft scoring.
- Protein expression levels of GSK3β, p-GSK3β, eEF2K, p-eEF2K, pro-MMP-2, MMP-2, collagen I, collagen III, and α-SMA were analyzed via Western blot.
Main Results:
- Bleomycin induced significant pulmonary fibrosis, characterized by increased fibrosis scores and elevated expression of fibrosis markers.
- GSK3β activation correlated with increased phosphorylation of eEF2K at Ser70, Ser392, and Ser470.
- Inhibition of GSK3β with TDZD-8 reduced fibrosis scores and suppressed the expression of fibrosis-related proteins, including MMP-2, collagen I, collagen III, and α-SMA.
- TDZD-8 treatment also increased eEF2K expression while decreasing its phosphorylation, suggesting a feedback mechanism.
Conclusions:
- GSK3β activates eEF2K through phosphorylation, promoting the formation and progression of pulmonary fibrosis.
- Targeting the GSK3β/eEF2K pathway with inhibitors like TDZD-8 demonstrates therapeutic potential for mitigating pulmonary fibrosis and lung tissue damage.

